
#1 open label hater | Opinions are my own
Joined February 2026
- Tweets434
- Following74
- Followers92
- Likes1.7K
James Ryan retweeted
FDA statement on $CAPR is nearly unprecedented. We must send the message via the @USDOJ, which I am absolutely loathe to recommend on anyone for obvious reasons, that manipulating clinical trial data is the worst possible crime in biotech and life sciences.
cc @linda_marban @AGToddBlanche
And justice is served… $CAPR
Can’t be making up data to profit off dying children
The FDA rejected $CAPR deramiocel. Finally, the Duchenne madness has stopped. Well done, FDA.
fda.gov/vaccines-blood-biolo…
9
913
$ABVX fires back - Statement on Short Seller Report
ir.abivax.com/news-releases/…
James Ryan retweeted
me: "please summarize and evaluate the claims made in this short report"
Claude: "read one page. deciding whether or not to read the rest of the report."
AI is getting a little too human-like
$ABVX so Scorpion argue that obe accumulates more in fat, but they also say it's 1 million times more distributive in water than octanol (slide 69)
I'm starting to think these guys don't know what they're talking about...
$ABVX just another generational opportunity. That report is a load of total, utter crap lmao
1
296
James Ryan retweeted
I guess this is what happens when you have the worst retail investors of all time
$SVRA FDA will not meet PDUFA target action date (11/22/2026) for molgramostim inhalation solution BLA, no new target data has been communicated
investors.savarapharma.com/n…
282
$HELP to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
ir.helus.com/news-releases/n…
5
564
James Ryan retweeted
$ARWR RBC PT 💯 notes no read through from
the $IONS slow start and reiterated $3-4b peak sales potential. Initial focus
will be in the high-risk population (TG≥880 without AP history and ≥500
with AP history) as ARWR notes 9 patients needed to treat to prevent
one AP at one year among those at high risk and only 3 for the latter
subgroup. On the pipeline, ALK7/INHBE data is on track for YE-26 (obese
non-diabetic monotherapy and GLP-1 combo in obese with T2D), HoFH
will read out pivotal in mid-27, PCSK9/APOC3 dimer update is mid-27
(regulatory approach revolves around LDL lowering)
$COAG concerned about decision to run single-arm GT study AGAINST the recommendation of FDA. Probably why down so much yesterday
ir.hemab.com/news-releases/n…
Among patients with hypertension due to primary aldosteronism, reductions in blood pressure and the aldosterone-to-renin ratio persisted for 2 years after completion of an extended course of aldosterone synthase inhibition. Full study results: nej.md/4jXjULO
#ScientificSessions26 | @AHAScience

ALT A bar graph titled "Systolic Blood Pressure." The y-axis shows mean pressure in mm Hg from 70 to 170. The x-axis has two sections: "Prestudy" with values 1 and 2, and "Post-Treatment" with 6 months, 1 year, and 2 years. Bars represent mean pressure with sample size noted: 9 and 14 for Prestudy, and 8, 8, and 11 for Post-Treatment. Error bars are included.
2
172
FDA has gone totally the other way in approving everything recently. It’s incredibly important not to let non-efficacious, dangerous products onto the market under the guise of ‘unmet patient need’
Mainly $CAPR ⬇️ but also $QURE which is yet to demonstrate any meaningful benefit
$CAPR I am more convinced than ever the FDA is going to reject deramiocel at the end of the month.
Why?
Because if all was going well with the review, and Capricor was confident the FDA was going to approve its cell therapy, Dr. Craig McDonald would not have publicly posted this letter submitted to the FDA — one month before the PDUFA date.
lnkd.in/p/gCCH65Mk
The only reason McDonald made this letter public was because Capricor knows its application is in trouble, therefore it is trying to apply more public pressure to get the FDA to change its mind.
5
4
2,013











